Table 3. Univariate analysis in overall survival and progression-free survival.
| |
Overall survival |
Progression-free survival |
||
|---|---|---|---|---|
| Variables | 5-year survival rate (%) | P-value | 5-year survival rate (%) | P-value |
|
Age | ||||
| ⩽65 years/>65 years |
64.8/56.3 |
0.383 |
61.8/68.3 |
0.504 |
|
Sex | ||||
| Male/Female |
58.9/71.2 |
0.847 |
62.3/72.4 |
0.585 |
|
Differentiation | ||||
| WD or MD/PD |
64.6/43.6 |
0.090 |
40.0/37.8 |
0.037 |
|
Stage | ||||
| I or II/III or IV |
73.4/34.2 |
0.003 |
72.1/46.9 |
0.103 |
|
Primary tumour status | ||||
| T1-2/T3-4 |
65.6/23.1 |
0.112 |
66.9/36.4 |
0.785 |
|
Lymphatic permeation | ||||
| Positive/Negative |
39.6/74.3 |
0.007 |
43.7/77.7 |
0.004 |
|
Vascular invasion | ||||
| Positive/Negative |
32.3/72.7 |
0.001 |
50.5/70.6 |
0.140 |
|
Resected status | ||||
| Positive/Negative |
54.5/63.0 |
0.806 |
59.3/66.8 |
0.715 |
|
Adjuvant chemotherapy | ||||
| Yes/No |
40.7/71.1 |
0.217 |
42.3/73.3 |
0.058 |
|
LAT1 | ||||
| High/Low |
37.8/90.1 |
<0.001 |
53.0/81.8 |
0.009 |
|
ASCT2 | ||||
| Positive/Negative |
39.4/82.3 |
0.012 |
39.2/79.5 |
0.033 |
|
xCT | ||||
| Positive/Negative |
52.5/73.5 |
0.140 |
67.5/65.9 |
0.791 |
|
4F2hc | ||||
| High/Low |
41.9/75.8 |
0.012 |
47.9/79.0 |
0.023 |
|
Ki-67 | ||||
| High/Low |
46.8/73.3 |
0.036 |
48.1/81.2 |
0.001 |
|
CD34 | ||||
| High/Low |
48.9/75.3 |
0.182 |
68.7/72.1 |
0.617 |
|
p53 | ||||
| Positive/Negative | 49.8/71.6 | 0.111 | 60.2/70.4 | 0.542 |
Abbreviations: ASCT2=ASC amino-acid transporter 2; LAT1=L-type amino-acid transporter1; MD=moderate differentiated; PD=poorly differentiated; WD=well differentiated.
The bold entries show a statistically significant difference.